Blanc SVSE 5 - Sciences de la vie, de la santé et des écosystèmes : Physique, chimie du vivant et innovations biotechnologiques

Control of tolloid proteinase activity in tissue remodelling: structural determination of regulatory mechanisms and design of novel inhibitors and activity-based probes – TOLLREG

The mechanisms by which tolloid proteinase activity is controlled by endogenous regulatory proteins (activators, inhibitors) are studied by structural approaches (crystallography, small angle X-ray scattering) coupled with site-directed mutagenesis. The results obtained serve to optimise the structures of potential inhibitors obtained by chemical synthesis that are subsequently tested in the presence of target proteases and fluorescent substrates.

Several major results have already been obtained in the course of the project. Most importantly, the first 3D crystallographic structure of a procollagen C-propeptide domain (from human procollagen type III) has been obtained. This provides information on the mechanism of intracellular assembly of collagen molecules and opens the way towards the development of strategies capable of preventing collagen trimerization. In addition, the determination of the low resolution structure of the complex between the procollagen III C-propeptide and the activating protein PCPE-1, together with site-directed mutagenesis, have permitted localisation of the interaction site as well as identification of key amino acids involved.
The mechanism of tolloid proteinase inhibition by the protein Sizzled has also been characterised in detail. It turns out that Sizzled efficiently and specifically inhibits all three of the major tolloid proteinases, having no effect on related proteinases tested (astacin, meprins, MMPs).
In parallel, several generations of potential phosphinate-based tolloid proteinase inhibitors have been prepared and tested. Encouraging results have already been obtained (inhibition constants of the order of 100 nM) with several molecules currently in the process of optimisation.

The project has made and continues to make major advances in understanding the mechanisms of regulation of tolloid proteinase activity. These results open up several possibilities for modifying this activity for therapeutic applications, including inhibition of tolloid proteinases, inhibition of the intracellular trimerization of collagens and inhibition of the interaction of procollagens with PCPEs. The development of synthetic tolloid proteinase inhibitors represents a first possible application and numerous others can be envisaged (blocking antibodies, chimeras derived from endogenous inhibitors, etc). These molecules could be rapidly tested using in vivo models of fibrosis and scarring currently available.

1 patent application (partners 1 and 2) filed 16/11/11 on the use of the structural data for the development of new therapeutic strategies
- 2 papers on the structure of the procollagen III C-propeptide in Nature Structural and Molecular Biology and Acta Crystallographica F (partners 1 et 2)
- 1 paper on the mechanism of action of Sizzled in the Journal of Biological Chemistry (partners 1 and 3)
- 1 paper on the interaction of procollagen III with PCPE-1 in the Journal of Biological Chemistry (partner 1)
- 1 book chapter on the functions and regulation of tolloid proteinases (partner 1)

Submission summary

Fibrotic diseases (sometimes known as scarring) are the most important causes of mortality worldwide. They are the common consequence of multiple initiating events (trauma, infection, surgery …) and affect multiple organs, including the cardiovascular system, lungs, liver, skin and cornea. Fibrosis is a form of defective tissue repair, characterised by increased cell proliferation and deposition of extracellular matrix, notably fibrillar collagens. It is the result of a complex chain of events involving inflammation, tissue repair and remodelling. In view of this complexity, several strategies have been proposed to prevent or treat fibrosis, though most of these suffer from a general lack of specificity. Particularly promising targets are the procollagen C-proteinases (also known as tolloid proteinases), the extracellular enzymes that trigger collagen fibril formation by release of the C-propeptides from soluble procollagen precursors.
Recent work has shown that tolloids are subject to complex regulation at the protein level, involving a number of endogenous activators and inhibitors. Among the activators, the most extensively studied are the procollagen C-proteinase enhancers (PCPEs) which have the unusual property of increasing tolloid proteinase activity, up to 20-fold, in a substrate specific manner, making them potential anti-fibrotic targets in their own right. As for inhibition, the first protein inhibitor of tolloid proteinases has recently been identified, called Sizzled, thus opening up new potential routes for therapeutic applications. Finally, a number of synthetic inhibitors of tolloid proteinases have been developed, though most are based on hydroxamate technology which has a number of drawbacks.
The overall goals of the proposed project are to: (a) understand the mechanism of action of the major PCPE, by high resolution structure determination in complex with its protein target, the C-propeptide trimer of fibrillar procollagens, (b) understand the mechanisms of action of the endogenous inhibitor Sizzled, and related proteins, by interaction, mutagenesis and structural studies, and (c) develop specific phosphinic based inhibitors and activity-based probes for tolloid proteinases, by structure based design. The project is timely in that we have recently obtained crystals of the C-propeptide trimer and have isolated a stable complex with PCPE. This and the recent determination of the 3D structure of a tolloid catalytic domain make a structural approach feasible, with a high probability of success. With regard to Sizzled, since this protein was originally identified in Xenopus and has no human counterpart, understanding the mechanism of action could provide new avenues for the development of highly specific tolloid inhibitors. Concerning synthetic molecules, phosphinic peptide inhibitors, developed by one of the partners, have shown high potency against a related zinc metalloproteinase from crayfish which suggests that such inhibitors could also be developed for tolloids. Finally, a particularly novel part of the project is the development of activity-based probes that will permit for the first time detection of tolloid proteinase activity in complex biological tissues and extracts.
The knowledge acquired during the course of the proposed project will form the basis for the development of new therapeutic strategies in the prevention and treatment of fibrotic disorders, where the world market is of the order of billions of euros. In the shorter term, it will provide new molecules and tools to gain further understanding of the mechanisms of tissue remodelling. The project is both innovative and multidisciplinary in that it will establish a new consortium, and bring together leaders in the field in the French scientific community (Moali, Aghajari, Dive), combining structural biology, chemical and biochemical approaches to tackle different mechanisms of tolloid proteinase regulation.

Project coordination

Catherine MOALI (CNRS - DELEGATION REGIONALE RHONE-AUVERGNE) – c.moali@ibcp.fr

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CNRS CNRS - DELEGATION REGIONALE RHONE-AUVERGNE
CNRS CNRS - DELEGATION REGIONALE RHONE-AUVERGNE
CEA CEA - CENTRE D'ETUDES NUCLEAIRES SACLAY

Help of the ANR 485,000 euros
Beginning and duration of the scientific project: - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter